Cargando…

SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia

BACKGROUND: Heterogeneity of the population in relation to infection, COVID-19 vaccination, and host characteristics is likely reflected in the underlying SARS-CoV-2 antibody responses. METHODS: We measured IgM, IgA, and IgG levels against SARS-CoV-2 spike and nucleocapsid antigens in 1076 adults of...

Descripción completa

Detalles Bibliográficos
Autores principales: Karachaliou, Marianna, Moncunill, Gemma, Espinosa, Ana, Castaño-Vinyals, Gemma, Rubio, Rocío, Vidal, Marta, Jiménez, Alfons, Prados, Esther, Carreras, Anna, Cortés, Beatriz, Blay, Natàlia, Bañuls, Marc, Pleguezuelos, Vanessa, Melero, Natalia Rodrigo, Serra, Pau, Parras, Daniel, Izquierdo, Luis, Santamaría, Pere, Carolis, Carlo, Papantoniou, Kyriaki, Goldberg, Ximena, Aguilar, Ruth, Garcia-Aymerich, Judith, de Cid, Rafael, Kogevinas, Manolis, Dobaño, Carlota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479347/
https://www.ncbi.nlm.nih.gov/pubmed/36109713
http://dx.doi.org/10.1186/s12916-022-02547-2
_version_ 1784790769291231232
author Karachaliou, Marianna
Moncunill, Gemma
Espinosa, Ana
Castaño-Vinyals, Gemma
Rubio, Rocío
Vidal, Marta
Jiménez, Alfons
Prados, Esther
Carreras, Anna
Cortés, Beatriz
Blay, Natàlia
Bañuls, Marc
Pleguezuelos, Vanessa
Melero, Natalia Rodrigo
Serra, Pau
Parras, Daniel
Izquierdo, Luis
Santamaría, Pere
Carolis, Carlo
Papantoniou, Kyriaki
Goldberg, Ximena
Aguilar, Ruth
Garcia-Aymerich, Judith
de Cid, Rafael
Kogevinas, Manolis
Dobaño, Carlota
author_facet Karachaliou, Marianna
Moncunill, Gemma
Espinosa, Ana
Castaño-Vinyals, Gemma
Rubio, Rocío
Vidal, Marta
Jiménez, Alfons
Prados, Esther
Carreras, Anna
Cortés, Beatriz
Blay, Natàlia
Bañuls, Marc
Pleguezuelos, Vanessa
Melero, Natalia Rodrigo
Serra, Pau
Parras, Daniel
Izquierdo, Luis
Santamaría, Pere
Carolis, Carlo
Papantoniou, Kyriaki
Goldberg, Ximena
Aguilar, Ruth
Garcia-Aymerich, Judith
de Cid, Rafael
Kogevinas, Manolis
Dobaño, Carlota
author_sort Karachaliou, Marianna
collection PubMed
description BACKGROUND: Heterogeneity of the population in relation to infection, COVID-19 vaccination, and host characteristics is likely reflected in the underlying SARS-CoV-2 antibody responses. METHODS: We measured IgM, IgA, and IgG levels against SARS-CoV-2 spike and nucleocapsid antigens in 1076 adults of a cohort study in Catalonia between June and November 2020 and a second time between May and July 2021. Questionnaire data and electronic health records on vaccination and COVID-19 testing were available in both periods. Data on several lifestyle, health-related, and sociodemographic characteristics were also available. RESULTS: Antibody seroreversion occurred in 35.8% of the 64 participants non-vaccinated and infected almost a year ago and was related to asymptomatic infection, age above 60 years, and smoking. Moreover, the analysis on kinetics revealed that among all responses, IgG RBD, IgA RBD, and IgG S2 decreased less within 1 year after infection. Among vaccinated, 2.1% did not present antibodies at the time of testing and approximately 1% had breakthrough infections post-vaccination. In the post-vaccination era, IgM responses and those against nucleoprotein were much less prevalent. In previously infected individuals, vaccination boosted the immune response and there was a slight but statistically significant increase in responses after a 2nd compared to the 1st dose. Infected vaccinated participants had superior antibody levels across time compared to naïve-vaccinated people. mRNA vaccines and, particularly the Spikevax, induced higher antibodies after 1st and 2nd doses compared to Vaxzevria or Janssen COVID-19 vaccines. In multivariable regression analyses, antibody responses after vaccination were predicted by the type of vaccine, infection age, sex, smoking, and mental and cardiovascular diseases. CONCLUSIONS: Our data support that infected people would benefit from vaccination. Results also indicate that hybrid immunity results in superior antibody responses and infection-naïve people would need a booster dose earlier than previously infected people. Mental diseases are associated with less efficient responses to vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02547-2.
format Online
Article
Text
id pubmed-9479347
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94793472022-09-17 SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia Karachaliou, Marianna Moncunill, Gemma Espinosa, Ana Castaño-Vinyals, Gemma Rubio, Rocío Vidal, Marta Jiménez, Alfons Prados, Esther Carreras, Anna Cortés, Beatriz Blay, Natàlia Bañuls, Marc Pleguezuelos, Vanessa Melero, Natalia Rodrigo Serra, Pau Parras, Daniel Izquierdo, Luis Santamaría, Pere Carolis, Carlo Papantoniou, Kyriaki Goldberg, Ximena Aguilar, Ruth Garcia-Aymerich, Judith de Cid, Rafael Kogevinas, Manolis Dobaño, Carlota BMC Med Research Article BACKGROUND: Heterogeneity of the population in relation to infection, COVID-19 vaccination, and host characteristics is likely reflected in the underlying SARS-CoV-2 antibody responses. METHODS: We measured IgM, IgA, and IgG levels against SARS-CoV-2 spike and nucleocapsid antigens in 1076 adults of a cohort study in Catalonia between June and November 2020 and a second time between May and July 2021. Questionnaire data and electronic health records on vaccination and COVID-19 testing were available in both periods. Data on several lifestyle, health-related, and sociodemographic characteristics were also available. RESULTS: Antibody seroreversion occurred in 35.8% of the 64 participants non-vaccinated and infected almost a year ago and was related to asymptomatic infection, age above 60 years, and smoking. Moreover, the analysis on kinetics revealed that among all responses, IgG RBD, IgA RBD, and IgG S2 decreased less within 1 year after infection. Among vaccinated, 2.1% did not present antibodies at the time of testing and approximately 1% had breakthrough infections post-vaccination. In the post-vaccination era, IgM responses and those against nucleoprotein were much less prevalent. In previously infected individuals, vaccination boosted the immune response and there was a slight but statistically significant increase in responses after a 2nd compared to the 1st dose. Infected vaccinated participants had superior antibody levels across time compared to naïve-vaccinated people. mRNA vaccines and, particularly the Spikevax, induced higher antibodies after 1st and 2nd doses compared to Vaxzevria or Janssen COVID-19 vaccines. In multivariable regression analyses, antibody responses after vaccination were predicted by the type of vaccine, infection age, sex, smoking, and mental and cardiovascular diseases. CONCLUSIONS: Our data support that infected people would benefit from vaccination. Results also indicate that hybrid immunity results in superior antibody responses and infection-naïve people would need a booster dose earlier than previously infected people. Mental diseases are associated with less efficient responses to vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02547-2. BioMed Central 2022-09-16 /pmc/articles/PMC9479347/ /pubmed/36109713 http://dx.doi.org/10.1186/s12916-022-02547-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Karachaliou, Marianna
Moncunill, Gemma
Espinosa, Ana
Castaño-Vinyals, Gemma
Rubio, Rocío
Vidal, Marta
Jiménez, Alfons
Prados, Esther
Carreras, Anna
Cortés, Beatriz
Blay, Natàlia
Bañuls, Marc
Pleguezuelos, Vanessa
Melero, Natalia Rodrigo
Serra, Pau
Parras, Daniel
Izquierdo, Luis
Santamaría, Pere
Carolis, Carlo
Papantoniou, Kyriaki
Goldberg, Ximena
Aguilar, Ruth
Garcia-Aymerich, Judith
de Cid, Rafael
Kogevinas, Manolis
Dobaño, Carlota
SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
title SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
title_full SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
title_fullStr SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
title_full_unstemmed SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
title_short SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
title_sort sars-cov-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in catalonia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479347/
https://www.ncbi.nlm.nih.gov/pubmed/36109713
http://dx.doi.org/10.1186/s12916-022-02547-2
work_keys_str_mv AT karachalioumarianna sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT moncunillgemma sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT espinosaana sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT castanovinyalsgemma sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT rubiorocio sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT vidalmarta sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT jimenezalfons sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT pradosesther sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT carrerasanna sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT cortesbeatriz sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT blaynatalia sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT banulsmarc sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT pleguezuelosvanessa sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT meleronataliarodrigo sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT serrapau sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT parrasdaniel sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT izquierdoluis sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT santamariapere sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT caroliscarlo sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT papantonioukyriaki sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT goldbergximena sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT aguilarruth sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT garciaaymerichjudith sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT decidrafael sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT kogevinasmanolis sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia
AT dobanocarlota sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia